H.C. Wainwright analyst Raghuram Selvaraju initiated coverage of NervGen Pharma (NGEN) with a Buy rating and $18 price target The company is developing therapies for devastating neurological conditions, the analyst tells investors in a research note. The firm says NervGen’s lead candidate, NVG-291, is entering Phase 3 development for chronic tetraplegia in patients with incomplete cervical spinal cord injury. It believes the drug offers a “differentiated” mechanism based on key scientific principles.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NGEN:
- NervGen Pharma initiated with a Buy at Lucid Capital
- NervGen Pharma price target raised to $12 from $10 at Maxim
- NervGen Wins FDA Alignment for Phase 3 RESTORE Trial in Chronic Tetraplegia
- NervGen Pharma aligns with FDA on RESTORE study following End-of-Phase 2 meeting
- NervGen Pharma price target lowered to $5.50 from $6.75 at Stifel